Add to Calendar
9/22/2020 11:00:00 AM9/22/2020 11:30:00 AM MassBio Town Hall w/ Special Guest Abbie Celniker, Partner, Third Rock VenturesWebinar, click "live-stream" button to view
MassBio’s President & CEO, Bob Coughlin, will host a bi-weekly virtual Town Hall for members, taking place every Tuesday at 11am. This will be an opportunity for our members to ask questions, hear what MassBio is up to, and learn more about the state of the industry amidst the COVID-19 pandemic.
For this week's Town Hall, Bob will be joined by Dr. Abbie Celniker, Partner at Third Rock Ventures, to discuss how startups are faring during the COVID pandemic, the general VC investment climate, and how small biotechs are trying to create a diverse and inclusive culture from the start.
Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only.
NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
MassBio Immediate Past Chair & Partner at Third Rock Ventures
Abbie Celniker joined Third Rock in 2016 bringing 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of our portfolio companies and has assumed active leadership roles in the following:
Board member of Cedilla Therapeutics
Chairman of the board and former interim chief executive officer of Rheos Medicines
Board member and former interim chief executive officer of Goldfinch Bio
Former president and chief executive officer of Sesen Bio
Prior to joining the firm, she served as president and CEO of Eleven Biotherapeutics (now Sesen Bio) since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. Abbie is a member of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.
Abbie loves doing jigsaw puzzles, but never looks at the picture on the box, and she once completed a 1000-piece puzzle that was solid white.
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them.
Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.